As healthcare providers (HCPs) are increasingly relying on evidence-based data and clinical guidelines, life science organizations must shift their focus to enabling HCPs in the effective adoption of these medicines. Medical affairs teams and medical science liaisons (MSLs) play a critical role in the success of therapies reaching clinical care and improving medication adherence.
By engaging with HCPs in meaningful conversations, bridging care gaps, and increasing scientific share of voice, medical affairs teams can ensure that the right therapies are adopted to improve patient outcomes. In this video, we discuss how medical affairs teams and MSLs can drive successful adoption of therapies by closing care gaps and increasing scientific share of voice.
Life Sciences organizations want their therapies to be adopted, and guideline medicine to be used – learn the critical steps to get there.
In a recent webinar with FierceBiotech, H1 explored this topic. Our expert panel:
Group Vice President of Strategic Solutions, H1
Vice President Medical Affairs Solid Tumor, JOHNSON & JOHNSON
Watch the video below to learn more.